TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact 中文

Press Release

25

Oct, 2017

MabSpace Biosciences Submits Investigational New Drug Application for its Second Generation PD-L1 Antibody With pH-Dependent Antigen Binding Property

(BUSINESS WIRE)--MabSpace Biosciences Co., Ltd., today announced it has filed an IND application to CFDA on September 12th, 2017 for MSB2311, a second-generation PD-L1 antibody with pH-dependent antigen binding property.

14

Mar, 2017

HJB and G-CON Manufacturing Announce Collaboration on State of the Art Bioprocess Facility in China

HJB and G-CON Manufacturing today announced that the companies are working together on HJB’s state of the art biologics facility in the Hangzhou Economic & Technology Development Area (HEDA) in China.

23

Feb, 2017

MabSpace Biosciences to Present Preclinical Data on Second Generation PD-L1 Antibody with pH-Dependent Antigen Binding Property at Upcoming Inaugural ASCO-SITC Clinical Immuno-Oncology Symposium

(BUSINESS WIRE)--Suzhou-based MabSpace Biosciences announced that the preclinical data for its lead program MSB2311, a 2nd generation humanized PD-L1 blocking antibody with a unique pH-dependent antigen binding property, will be presented at the upcoming 2017 Inaugural American Society of Clinical Oncology (ASCO)-Society for Immunotherapy of Cancer (SITC) Annual Meeting on February 23rd-25th, 2017 in Orlando, Florida, US.

05

Jan, 2017

Ambrx and MabSpace Biosciences to Collaborate on Novel Antibody Drug Conjugates

(BUSINESS WIRE)--San Diego based Ambrx Inc. and Suzhou based MabSpace Biosciences have agreed to collaborate on discovery and development of multiple novel ADCs in China and around the world for oncology.

21

May, 2015

GenorBio, Walvax’s mAb Arm, Partners With MabSpace Biosciences to Discover and Develop Novel Antibody Therapeutics

(BUSINESS WIRE)--MabSpace Biosciences Co., Ltd announced today that it has signed a collaborative contract of a novel therapeutic antibody with Genor Biopharma Co. Ltd (GenorBio), the mAb division of Walvax Group, one of the leading therapeutic antibody development companies in China.

19

May, 2015

Hengrui to Collaborate With MabSpace on Novel Antibody Therapeutics

(BUSINESS WIRE)--MabSpace Biosciences Co., Ltd. announced today that it has signed a collaborative contract with Jiangsu Hengrui Medicine Co., Ltd, one of the leading innovative pharmaceutical companies in China, to co-develop novel antibody therapeutics on two targets.

1 2 3 4 5